Sera Prognostics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 74

Employees

  • Stock Symbol
  • SERA

Stock Symbol

  • Share Price
  • $8.75
  • (As of Wednesday Closing)

Sera Prognostics General Information

Description

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2749 East Parleys Way
  • Suite 200
  • Salt Lake City, UT 84109
  • United States
+1 (801)
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2749 East Parleys Way
  • Suite 200
  • Salt Lake City, UT 84109
  • United States
+1 (801)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sera Prognostics Stock Performance

As of 06-Nov-2024, Sera Prognostics’s stock price is $8.75. Its current market cap is $292M with 33.4M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.75 $7.65 $1.65 - $12.36 $292M 33.4M 86.2K -$0.99

Sera Prognostics Financials Summary

As of 30-Sep-2024, Sera Prognostics has a trailing 12-month revenue of $94K.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 210,692 143,378 (48,340) 91,071
Revenue 94 306 268 82
EBITDA (34,024) (36,927) (43,825) (33,749)
Net Income (32,244) (36,242) (44,186) (35,009)
Total Assets 79,001 95,441 116,329 147,029
Total Debt 1,100 1,858 2,831 128
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sera Prognostics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sera Prognostics‘s full profile, request access.

Request a free trial

Sera Prognostics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Sera Prognostics‘s full profile, request access.

Request a free trial

Sera Prognostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's
Diagnostic Equipment
Salt Lake City, UT
74 As of 2024

Seattle, WA
 

Irvine, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sera Prognostics Competitors (9)

One of Sera Prognostics’s 9 competitors is RareCyte, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RareCyte Venture Capital-Backed Seattle, WA
OncoCyte Formerly VC-backed Irvine, CA
Biodesix Formerly VC-backed Louisville, CO
GRAIL Formerly VC-backed Menlo Park, CA
BioGenex Laboratories Corporation Fremont, CA
You’re viewing 5 of 9 competitors. Get the full list »

Sera Prognostics Patents

Sera Prognostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023219174-A1 Shbg and ibp4 antibodies and methods using same Pending 09-Feb-2022
CA-3220282-A1 Biomarker pairs and triplets for predicting preterm birth Pending 21-May-2021
US-20240264170-A1 Biomarker pairs and triplets for predicting preterm birth Pending 21-May-2021
EP-3894581-A2 Nucleic acid biomarkers for placental dysfunction Inactive 10-Dec-2018
AU-2019397427-A1 Nucleic acid biomarkers for placental dysfunction Inactive 10-Dec-2018 C12Q1/6883
To view Sera Prognostics’s complete patent history, request access »

Sera Prognostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sera Prognostics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

23.89 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,638

Rank

Percentile

Healthcare

Industry

of 636

Rank

Percentile

Medical Services

Subindustry

of 115

Rank

Percentile

To view Sera Prognostics’s complete esg history, request access »

Sera Prognostics FAQs

  • When was Sera Prognostics founded?

    Sera Prognostics was founded in 2008.

  • Where is Sera Prognostics headquartered?

    Sera Prognostics is headquartered in Salt Lake City, UT.

  • What is the size of Sera Prognostics?

    Sera Prognostics has 74 total employees.

  • What industry is Sera Prognostics in?

    Sera Prognostics’s primary industry is Diagnostic Equipment.

  • Is Sera Prognostics a private or public company?

    Sera Prognostics is a Public company.

  • What is Sera Prognostics’s stock symbol?

    The ticker symbol for Sera Prognostics is SERA.

  • What is the current stock price of Sera Prognostics?

    As of 06-Nov-2024 the stock price of Sera Prognostics is $8.75.

  • What is the current market cap of Sera Prognostics?

    The current market capitalization of Sera Prognostics is $292M.

  • What is Sera Prognostics’s current revenue?

    The trailing twelve month revenue for Sera Prognostics is $94K.

  • Who are Sera Prognostics’s competitors?

    RareCyte, OncoCyte, Biodesix, GRAIL, and BioGenex Laboratories are some of the 9 competitors of Sera Prognostics.

  • What is Sera Prognostics’s annual earnings per share (EPS)?

    Sera Prognostics’s EPS for 12 months was -$0.99.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »